http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Innovation Height and Firm Performance: An Empirical Analysis from the Community Innovation Survey
ISOGAWA, DAIYA,NISHIKAWA, KOHEI,OHASHI, HIROSHI Korea Development Institute 2015 KDI Journal of Economic Policy (KDI JEP) Vol.37 No.1
This study evaluates the economic impact of product innovation by using firm-level data from the Community Innovation Survey conducted in Japan. It accounts for possible technological spillover from innovation activities and examines the extent to which new-to-market product innovations contribute to firm performance. Econometric analysis using a simultaneous equation model reveals that new-to-market product innovation is likely to increase a firm's sales without cannibalizing those of existing products and generate more technological spillover to other firms. Moreover, such innovation is more likely to emerge from firms collaborating with academic institutions. The paper concludes by discussing policy implications of these findings as well as points to the importance of cross-country comparison between Korea and Japan.
Chronological Switch from Translesion Synthesis to Homology-Dependent Gap Repair In Vivo
Shingo Fujii,Asako Isogawa,Robert P. Fuchs 한국독성학회 2018 Toxicological Research Vol.34 No.4
Cells are constantly exposed to endogenous and exogenous chemical and physical agents that damage their genome by forming DNA lesions. These lesions interfere with the normal functions of DNA such as transcription and replication, and need to be either repaired or tolerated. DNA lesions are accurately removed via various repair pathways. In contrast, tolerance mechanisms do not remove lesions but only allow replication to proceed despite the presence of unrepaired lesions. Cells possess two major tolerance strategies, namely translesion synthesis (TLS), which is an error-prone strategy and an accurate strategy based on homologous recombination (homologydependent gap repair [HDGR]). Thus, the mutation frequency reflects the relative extent to which the two tolerance pathways operate in vivo. In the present paper, we review the present understanding of the mechanisms of TLS and HDGR and propose a novel and comprehensive view of the way both strategies interact and are regulated in vivo.
Innovation Height and Firm Performance: An Empirical Analysis from the Community Innovation Survey
Hiroshi Ohashi,Kohei Nishikawa,Daiya Isogawa 한국개발연구원 2015 KDI Journal of Economic Policy (KDI JEP) Vol.37 No.1
This study evaluates the economic impact of product innovation by using firm-level data from the Community Innovation Survey conducted in Japan. It accounts for possible technological spillover from innovation activities and examines the extent to which new-to-market product innovations contribute to firm performance. Econometric analysis using a simultaneous equation model reveals that new-to-market product innovation is likely to increase a firm’s sales without cannibalizing those of existing products and generate more technological spillover to other firms. Moreover, such innovation is more likely to emerge from firms collaborating with academic institutions. The paper concludes by discussing policy implications of these findings as well as points to the importance of cross-country comparison between Korea and Japan.
( Satoshi Motoya ),( Mamoru Watanabe ),( Hyo Jong Kim ),( Young Ho Kim ),( Dong Soo Han ),( Hirotoshi Yuasa ),( Junichi Tabira ),( Naoki Isogawa ),( Shoko Arai ),( Isao Kawaguchi ),( Toshifumi Hibi ) 대한장연구학회 2018 Intestinal Research Vol.16 No.2
Background/Aims: Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily (BID) for 8 weeks. Clinical responders in OCTAVE Induction were re-randomized to 52 weeks’ therapy with placebo, tofacitinib 5 mg BID, or tofacitinib 10 mg BID. Methods: We conducted post-hoc efficacy and safety analyses of East Asian patients in OCTAVE Induction 1 and 2 and OCTAVE Sustain. Results: A total of 121 East Asian (Japan, Korea, and Taiwan) patients were randomized in OCTAVE Induction 1 and 2 (placebo, n=26; tofacitinib 10 mg BID, n=95), and 63 in OCTAVE Sustain (placebo, n=20; tofacitinib 5 mg BID, n=22; tofacitinib 10 mg BID, n=21). At week 8 of OCTAVE Induction 1 and 2, 18.9% of patients (18/95) achieved remission with tofacitinib 10 mg BID versus 3.8% (1/26) with placebo. In OCTAVE Sustain, the week 52 remission rates were 45.5% (10/22), 47.6% (10/21), and 15.0% (3/20) with 5 mg BID, 10 mg BID, and placebo, respectively. Adverse event rates were similar between groups in OCTAVE Induction and numerically higher with tofacitinib in OCTAVE Sustain. Serious adverse event rates were similar across groups in all studies. Infections were numerically more frequent with tofacitinib than placebo. Increases in serum lipid levels were observed with tofacitinib. Conclusions: In East Asian patients with UC, tofacitinib demonstrated numerically greater efficacy versus placebo as induction and maintenance therapy, with a safety profile consistent with the global study population. ClinicalTrials.gov: NCT01465763; NCT01458951; NCT01458574. (Intest Res 2018;16:233-245)